MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/bjsopen/zrae008

Медицинская библиотека · BJS open · 2024

Upfront surgery for stage IIIA/B non-small cell lung cancer: retrospective cohort study.

Deng Hongsheng, Liu Jun, Cai Xiuyu, Jiang Shunjun, Lu Weixiang, Ai Qing, Li Jianfu, Xiong Shan, Qin Xiangyun, Liang Wenhua, He Jianxing

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Stage III non-small cell lung cancer is a heterogeneous disease. Several international guidelines recommend neoadjuvant treatment before surgery; however, upfront surgery is the preferred approach for technically resectable non-small cell lung cancer in East Asia. The aim of this retrospective study was to evaluate the long-term outcomes of curative-intent upfront surgery in stage IIIA/B non-small cell lung cancer.

METHODS

Patients who underwent curative-intent upfront surgery with stage cIIIA/B non-small cell lung cancer were identified. The clinical and pathological variables and survival outcomes were evaluated.

RESULTS

Overall, 664 patients were identified, of whom 320 (48.8%) had N2 disease, 66.7% were males, 49.4% had a smoking history, and 61.2% had lung adenocarcinoma. Lobectomy was the most performed surgical procedure (84.9%). A total of 40 patients (6.02%) had positive margins (R1/R2). The grade III adverse event rate was 2.0% (13 of 664). The median follow-up was 30.6 (range 1.9-97.7) months. At follow-up, the mortality rate was 13.3% (88 of 664) and 37.2% of patients (247 of 664) had recurrence. Lung (101 of 247 (40.9%)) and brain (53 of 247 (21.5%)) were the most common sites of recurrence. The median overall survival was 60.0 (95% c.i. 51.5 to 67.6) months, with overall survival probability at 1, 2, 3, and 5 years being 89.6%, 77.8%, 67.2%, and 49.0% respectively. The R0 cohort showed an improved median overall survival compared with the R1/R2 cohort (67.4 versus 26.5 months respectively; P = greater than 0.001). The multivariable analysis revealed that age greater than or equal to 65 years (HR 1.51, 95% c.i. 1.08 to 2.12; reference = age less than 65 years), tumour size (greater than or equal to 5 cm (HR 2.13, 95% c.i. 1.41 to 3.21) and greater than or equal to 3 cm but less than 5 cm (HR 1.15, 95% c.i. 0.78 to 1.71); reference = less than 3 cm), and adjuvant treatment (chemotherapy (HR 0.69, 95% c.i. 0.49 to 0.96) and targeted therapy (HR 0.30, 95% c.i. 0.12 to 0.76); reference = none) significantly predicted overall survival.

CONCLUSION

Upfront surgery is an option for the management of stage IIIA/B non-small cell lung cancer.

Для цитирования: Deng Hongsheng, Liu Jun, Cai Xiuyu, Jiang Shunjun, Lu Weixiang, Ai Qing, Li Jianfu, Xiong Shan, Qin Xiangyun, Liang Wenhua, He Jianxing. Upfront surgery for stage IIIA/B non-small cell lung cancer: retrospective cohort study.. BJS open. 2024. DOI: 10.1093/bjsopen/zrae008.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.